Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Davide Bedognetti¹, Michele Ceccarelli², Lorenzo Galluzzi^{3

4

5}, Rongze Lu², Karolina Palucka⁶, Josue Samayoa², Stefani Spranger⁷, Sarah Warren⁸, Kwok-Kin Wong⁹, Elad Ziv¹⁰, Diego Chowell¹¹, Lisa M Coussens¹², Daniel D De Carvalho¹³, David G DeNardo¹⁴, Jérôme Galon¹⁵, Howard L Kaufman¹⁶, Tomas Kirchhoff¹⁷, Michael T Lotze¹⁸, Jason J Luke¹⁹, Andy J Minn²⁰, Katerina Politi²¹, Leonard D Shultz²², Richard Simon²³, Vésteinn Thórsson²⁴, Joanne B Weidhaas²⁵, Maria Libera Ascierto²⁶, Paolo Antonio Ascierto²⁷, James M Barnes², Valentin Barsan²⁸, Praveen K Bommareddy²⁹, Adrian Bot³⁰, Sarah E Church⁸, Gennaro Ciliberto³¹, Andrea De Maria³², Dobrin Draganov³³, Winson S Ho³⁴, Heather M McGee³⁵, Anne Monette³⁶, Joseph F Murphy³⁷, Paola Nisticò³¹, Wungki Park¹¹, Maulik Patel², Michael Quigley³⁸, Laszlo Radvanyi³⁹, Harry Raftopoulos⁴⁰, Nils-Petter Rudqvist³, Alexandra Snyder⁴¹, Randy F Sweis¹⁹, Sara Valpione⁴², Roberta Zappasodi^{43

44}, Lisa H Butterfield⁴⁵, Mary L Disis⁴⁶, Bernard A Fox⁴⁷, Alessandra Cesano⁸, Francesco M Marincola⁴⁸; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups

Affiliations

¹ Sidra Medicine, Doha, Qatar.
² AbbVie, Redwood City, CA, USA.
³ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
⁴ Sandra and Edward Meyer Cancer Center, New York, NY, USA.
⁵ Université Paris Descartes/Paris V, Paris, France.
⁶ The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
⁷ Koch Institute for Integrative Cancer Research at MIT, Cambridge, MT, USA.
⁸ NanoString Technologies, Inc, Seattle, WA, USA.
⁹ Perlmutter Cancer Center, New York Langone Health, New York, NY, USA.
¹⁰ University of California, San Francisco, CA, USA.
¹¹ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹² Oregon Health & Science University, Portland, OR, USA.
¹³ Department of Medical Biophysics, Princess Margaret Cancer Centre University Health Network, University of Toronto, Toronto, Canada.
¹⁴ Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
¹⁵ INSERM, Laboratory of Integrative Cancer Immunology, Equipe Labellisée Ligue Contre le Cancer, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot; Centre de Recherche des Cordeliers, F-75006, Paris, France.
¹⁶ Massachusetts General Hospital, Boston, MA, USA and Replimune, Inc, Woburn, MA, USA.
¹⁷ Perlmutter Comprehensive Cancer Center, New York University School of Medicine, New York University Langone Health New York, New York, NY, USA.
¹⁸ UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
¹⁹ University of Chicago, Chicago, IL, USA.
²⁰ Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA, USA.
²¹ Yale School of Medicine, New Haven, CT, USA.
²² The Jackson Laboratory Cancer Center, Bar Harbor, ME, USA.
²³ R. Simon Consulting, Potomac, MD, USA.
²⁴ Institute for Systems Biology, Seattle, WA, USA.
²⁵ University of California, Los Angeles, Los Angeles, CA, USA.
²⁶ MedImmune, Gaithersberg, MD, USA.
²⁷ Istituto Nazionale Tumori-IRCCS Fondazione 'G. Pascale', Naples, Italy.
²⁸ Stanford University, Stanford, CA, USA.
²⁹ Rutgers University, New Brunswick, NJ, USA.
³⁰ Kite, a Gilead Company, Santa Monica, CA, USA.
³¹ IRCCS Istituto Nazionale Tumori Regina Elena, Rome, Italy.
³² Università degli Studi di Genova and Ospedale Policlinico San Martino IRCCS, Genoa, Italy.
³³ Calidi Biotherapeutics, San Diego, CA, USA.
³⁴ Department of Neurosurgery, Division of Pediatric Neurosurgery, Primary Children's Hospital, University of Utah, Salt Lake City, UT, USA.
³⁵ Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³⁶ Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
³⁷ Caprion Biosciences Inc, Montreal, QC, Canada.
³⁸ Bristol-Myers Squibb Company, Redwood City, CA, USA.
³⁹ Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
⁴⁰ Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ, USA.
⁴¹ Merck & Co, Kenilworth, NJ, USA.
⁴² CRUK Manchester Institute and The Christie NHS Foundation Trust, The University of Manchester, Manchester, UK.
⁴³ Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴⁴ Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴⁵ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
⁴⁶ University of Washington, Seattle, WA, USA.
⁴⁷ Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR, USA.
⁴⁸ Refuge Biotechnologies Inc, 1505 Adams Drive, Suite D, Menlo Park, CA, 94025, USA. franco.marincola@refugebiotech.com.

PMID: 31272507
PMCID: PMC6610889
DOI: 10.1186/s40425-019-0640-y

Published Erratum

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Davide Bedognetti et al. J Immunother Cancer. 2019.

. 2019 Jul 4;7(1):167.

doi: 10.1186/s40425-019-0640-y.

Authors

Affiliations

¹ Sidra Medicine, Doha, Qatar.
² AbbVie, Redwood City, CA, USA.
³ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
⁴ Sandra and Edward Meyer Cancer Center, New York, NY, USA.
⁵ Université Paris Descartes/Paris V, Paris, France.
⁶ The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
⁷ Koch Institute for Integrative Cancer Research at MIT, Cambridge, MT, USA.
⁸ NanoString Technologies, Inc, Seattle, WA, USA.
⁹ Perlmutter Cancer Center, New York Langone Health, New York, NY, USA.
¹⁰ University of California, San Francisco, CA, USA.
¹¹ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹² Oregon Health & Science University, Portland, OR, USA.
¹³ Department of Medical Biophysics, Princess Margaret Cancer Centre University Health Network, University of Toronto, Toronto, Canada.
¹⁴ Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
¹⁵ INSERM, Laboratory of Integrative Cancer Immunology, Equipe Labellisée Ligue Contre le Cancer, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot; Centre de Recherche des Cordeliers, F-75006, Paris, France.
¹⁶ Massachusetts General Hospital, Boston, MA, USA and Replimune, Inc, Woburn, MA, USA.
¹⁷ Perlmutter Comprehensive Cancer Center, New York University School of Medicine, New York University Langone Health New York, New York, NY, USA.
¹⁸ UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
¹⁹ University of Chicago, Chicago, IL, USA.
²⁰ Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA, USA.
²¹ Yale School of Medicine, New Haven, CT, USA.
²² The Jackson Laboratory Cancer Center, Bar Harbor, ME, USA.
²³ R. Simon Consulting, Potomac, MD, USA.
²⁴ Institute for Systems Biology, Seattle, WA, USA.
²⁵ University of California, Los Angeles, Los Angeles, CA, USA.
²⁶ MedImmune, Gaithersberg, MD, USA.
²⁷ Istituto Nazionale Tumori-IRCCS Fondazione 'G. Pascale', Naples, Italy.
²⁸ Stanford University, Stanford, CA, USA.
²⁹ Rutgers University, New Brunswick, NJ, USA.
³⁰ Kite, a Gilead Company, Santa Monica, CA, USA.
³¹ IRCCS Istituto Nazionale Tumori Regina Elena, Rome, Italy.
³² Università degli Studi di Genova and Ospedale Policlinico San Martino IRCCS, Genoa, Italy.
³³ Calidi Biotherapeutics, San Diego, CA, USA.
³⁴ Department of Neurosurgery, Division of Pediatric Neurosurgery, Primary Children's Hospital, University of Utah, Salt Lake City, UT, USA.
³⁵ Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³⁶ Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
³⁷ Caprion Biosciences Inc, Montreal, QC, Canada.
³⁸ Bristol-Myers Squibb Company, Redwood City, CA, USA.
³⁹ Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
⁴⁰ Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ, USA.
⁴¹ Merck & Co, Kenilworth, NJ, USA.
⁴² CRUK Manchester Institute and The Christie NHS Foundation Trust, The University of Manchester, Manchester, UK.
⁴³ Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴⁴ Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴⁵ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
⁴⁶ University of Washington, Seattle, WA, USA.
⁴⁷ Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR, USA.
⁴⁸ Refuge Biotechnologies Inc, 1505 Adams Drive, Suite D, Menlo Park, CA, 94025, USA. franco.marincola@refugebiotech.com.

PMID: 31272507
PMCID: PMC6610889
DOI: 10.1186/s40425-019-0640-y

Abstract

Following publication of the original article [1], the author reported that an author name, Roberta Zappasodi, was missed in the authorship list.

PubMed Disclaimer

Erratum for

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups. Bedognetti D, et al. J Immunother Cancer. 2019 May 22;7(1):131. doi: 10.1186/s40425-019-0602-4. J Immunother Cancer. 2019. PMID: 31113486 Free PMC article. Review.

References

1. Bedognetti, et al. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immuno Ther Cancer. 2020;7:131. doi: 10.1186/s40425-019-0602-4. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Affiliations

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Authors

Affiliations

Abstract

Erratum for

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources